Institute of Radiation Medicine, Academy of Military Medical Sciences, Pla.

Beijing Stomatology Hospital, Capital Medical University

Beijing Sh Bio-Tech Corporation

Institute of Radiation Medicine Academy of Military Medical Science

Beijing Sanly Sci-Tech Develop Inc. Ltd.

Beijing Luyin Lihua Pharmaceutical Science and Technology Development Company Ltd

Zuze Wu

Aiping Yu

Bingxing Shi

Hua Wang

Qiang Li

Yu Cao

Yi Liu

Jinsong Wang

Zhongxiong Tang

Chuanling Zhang

Zhiyun Kang

Songling Wang

Jingchao Hu

Chunna Dong

Jianjin Bi

Yilin Xie

Zhuangrong Sun

Junlin Li

Wenqiang An

Lizhen Yuan

Chunping Cui

Shaojun Du

Danli Wu

Provided in the present invention are odontogenic stem cells and a use of genetically modified odontogenic stem cells for treating periodontal disease, repairing defects in periodontal bone tissues or soft tissues and/or promoting the regeneration of periodontal tissues, or in products for treating acute and chronic bone tissue injuries (e.g. bone fracture) or bone tissue defects. Also provided in the present invention is a composition comprising odontogenic stem cells and/or genetically modified odontogenic stem cells, wherein an exogenous hepatocyte growth factor gene is introduced into odontogenic stem cells through an adenovirus or adeno-associated virus vector to obtain the genetically modified odontogenic stem cells.

Usage of odontogenic stem cells and genetically modified odontogenic stem cells

Provided are a hepatopoietin PCn (HPPCn) and its homologous proteins, which can promote hepatocyte proliferation in vitro, promote liver regeneration in vivo, inhibit the growth of tumor cells and promote the apoptosis of tumor cells. The hepatopoietin PCn (HPPCn) and its homologous proteins are useful for the treatment of acute and chronic liver injury, or the treatment of liver fibrosis.

Hepatopoietin and use thereof

This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.

Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof

Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.

Preparation of low bleeding anticoagulant fusion protein and its use

The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.

Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes

This invention relates to a new use of stilbene derivatives or pharmaceutically acceptable salts thereof, especially in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus associated diseases.

Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases

Growing community of inventors

Beijing, China

Zuze Wu